Non-muscle Invasive Bladder Cancer
📧 Sign up to get email alerts when something new happens for Non-muscle Invasive Bladder Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-01-27Clinical Trial Update: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b) [Phase 1]
This clinical trial update reports safety and toxicity findings from a Phase 1b intravesical instillation study of TARA-002 in adults with h…
-
CLINICAL_TRIALS trial_result · 2025-01-27Clinical Trial Update: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) [Phase 1]
Phase 1a safety and toxicity study of intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder cancer. Th…
-
CLINICAL_TRIALS research · 2025-01-15Clinical Trial Update: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC [Phase 1]
A Phase 1 trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of SIM0237 alone or in combination with BCG …
-
CLINICAL_TRIALS trial_result · 2025-01-10Clinical Trial Update: Comparison of BCG RIVM and Russian Strains for Treating Non-Muscle-Invasive Bladder Cancer (NMIBC) [Phase 4]
Phase 4 clinical trial comparing BCG RIVM with Russian-strain BCG for non-muscle-invasive bladder cancer has completed.
-
CLINICAL_TRIALS research · 2025-01-09Clinical Trial Update: Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer [Phase 1, Phase 2]
A clinical trial update on BH011 evaluating safety, tolerability, and preliminary efficacy in non-muscle-invasive bladder cancer across Phas…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-12-16Clinical Trial Update: Pre-Habilitation with Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial) [NA]
A clinical trial from University of Virginia is investigating pre-habilitation with mindfulness and exercise for bladder cancer patients und…
-
CLINICAL_TRIALS research · 2024-12-11Clinical Trial Update: Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients [Phase 3]
Phase 3 trial evaluating atezolizumab plus one-year BCG instillations in BCG-naive high-risk non-muscle invasive bladder cancer patients; th…
-
CLINICAL_TRIALS research · 2024-12-04Clinical Trial Update: DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr [Phase 1, Phase 2]
A phase 1/2 clinical trial at University College London is evaluating durvalumab in combination with the S-488210/S-488211 vaccine for non-m…
-
CLINICAL_TRIALS research · 2024-12-03Clinical Trial Update: A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) [Phase 1]
A Phase I clinical trial update announcing recruitment for SHR-2005 intravesical instillation in patients with intermediate- and high-risk n…
-
CLINICAL_TRIALS trial_result · 2024-11-04Clinical Trial Update: A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer [Phase 3]
Update on a Phase 3 single-arm trial of UGN-102 for low-grade, intermediate-risk non-muscle invasive bladder cancer; results were posted in …
-
CLINICAL_TRIALS research · 2024-10-30Clinical Trial Update: Can Second Resection for pT1 Bladder Cancer be Avoided After Initial En-Bloc Resection With Negative Safety Margins
A Mansoura University trial is assessing whether a second transurethral resection for pT1 bladder cancer can be avoided after an initial en-…
-
CLINICAL_TRIALS trial_result · 2024-10-24Clinical Trial Update: LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors [Phase 1, Phase 2]
Terminated basket trial evaluating Lerapolturev with or without checkpoint inhibitors in solid tumors, including bladder cancer and non-musc…
-
CLINICAL_TRIALS research · 2024-10-10Clinical Trial Update: A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk. [Phase 2]
A Phase 2 clinical trial is evaluating the efficacy and safety of Disitamab Vedotin plus tislelizumab with re-TURBT in patients with HER-2-h…
-
CLINICAL_TRIALS research · 2024-10-09Clinical Trial Update: A Clinical Trial Aimed at Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder Cancer [Phase 1]
A Phase 1 clinical trial update describing a study of VT-101 for Non-muscle Invasive Bladder Cancer, currently recruiting to assess safety a…
-
CLINICAL_TRIALS trial_result · 2024-09-25Clinical Trial Update: Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin [Phase 2]
A Phase 2 study evaluating CG0070 in combination with pembrolizumab for non-muscle invasive bladder cancer unresponsive to Bacillus Calmette…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) [Phase 3]
Phase 3 trial update evaluating feasibility of at-home instillation of UGN-102 for low-grade non-muscle invasive bladder cancer. Results wer…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating SHR-1501 in combination with SHR-2005 for high-risk non-muscle invasive bladder cancer not complete…
-
CLINICAL_TRIALS trial_result · 2024-09-03Clinical Trial Update: MK-3475/BCG in High Risk Superficial Bladder Cancer [Phase 1]
Phase 1 trial evaluating pembrolizumab with Bacillus Calmette-Guérin in high-risk non-muscle invasive bladder cancer has completed and resul…
-
CLINICAL_TRIALS research · 2024-08-13Clinical Trial Update: Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC) [Phase 1]
A Phase 1 clinical trial update indicating that 9MW2821 is being evaluated for safety and efficacy in high-risk non-muscle-invasive bladder …
-
CLINICAL_TRIALS research · 2024-08-12Clinical Trial Update: OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating OH2 oncolytic viral therapy for non-muscle-invasive bladder cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2024-08-12Clinical Trial Update: The Impact of PDD During TURB for NMIBC [Phase 4]
Phase 4 trial update evaluating photodynamic diagnosis during transurethral resection of bladder tumor for non-muscle invasive bladder cance…
-
CLINICAL_TRIALS research · 2024-07-22Clinical Trial Update: Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer [Phase 2]
This document reports a Phase 2 clinical trial evaluating radiotherapy for BCG-unresponsive non-muscle-invasive bladder cancer in situ (CIS)…
-
CLINICAL_TRIALS trial_result · 2024-07-19Clinical Trial Update: A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer [Phase 1, Phase 2]
The study ALT-801 in patients with BCG-failure non-muscle invasive bladder cancer (Phase 1/2) was terminated, with results posted in 2024.
-
CLINICAL_TRIALS research · 2024-07-12Clinical Trial Update: Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment [Phase 1, Phase 2]
Clinical trial update evaluating camrelizumab for high-risk non-muscle-invasive bladder cancer that failed BCG treatment, spanning Phase 1 a…
-
CLINICAL_TRIALS research · 2024-07-12Clinical Trial Update: Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer [Phase 2]
Disitamab Vedotin is being studied in combination with Bacillus Calmette-Guérin (BCG) therapy for HER2-expressing high-risk non-muscle invas…